Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QR2K
|
|||
| Drug Name |
NKR-2 cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1], [2] | |
| Company |
Celyad (formerly named Cardio3 BioSciences)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NKG2 D activating NK receptor (KLRK1) | Target Info | CAR-T-Cell-Therapy | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | |||
| REF 2 | ClinicalTrials.gov (NCT03370198) Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.